{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human&page=16",
    "query": {
      "intervention": "Human",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 9649,
    "total_pages": 965,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T07:56:34.006Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00376324",
      "title": "Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Tigecycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2006-09",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2009-07-10",
      "last_synced_at": "2026-10-26T07:56:34.006Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00376324"
    },
    {
      "nct_id": "NCT04338659",
      "title": "A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Tumors Lymphomas"
      ],
      "interventions": [
        {
          "name": "IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2021-01-14",
      "completion_date": "2023-02-28",
      "has_results": false,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-10-26T07:56:34.006Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Westwood, Kansas • Jackson, Mississippi + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04338659"
    },
    {
      "nct_id": "NCT00355342",
      "title": "Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Salmeterol 50 mcg BID",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol 250/50 mcg BID",
          "type": "DRUG"
        },
        {
          "name": "DISKUS inhaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2004-04-28",
      "completion_date": "2007-09-06",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-10-26T07:56:34.006Z",
      "location_count": 37,
      "location_summary": "Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00355342"
    },
    {
      "nct_id": "NCT06012669",
      "title": "Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Immune Health"
      ],
      "interventions": [
        {
          "name": "High dose Human Lactoferrin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Low dose Human Lactoferrin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Active Control Bovine Lactoferrin",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Midwest Center for Metabolic and Cardiovascular Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 66,
      "start_date": "2023-09-06",
      "completion_date": "2023-12-27",
      "has_results": false,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-10-26T07:56:34.006Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Port Saint Lucie, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06012669"
    },
    {
      "nct_id": "NCT05644769",
      "title": "Chymase Angiotensin-(1-12) Axis In Hypertensive Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Determine the presence of Human sequence Ang-(1-12) on no medication",
          "type": "OTHER"
        },
        {
          "name": "Human sequence Ang-(1-12) on Lisinopril 40mg every day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Trinity Hypertension & Metabolic Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2022-11-15",
      "completion_date": "2023-03-31",
      "has_results": false,
      "last_update_posted_date": "2022-12-09",
      "last_synced_at": "2026-10-26T07:56:34.006Z",
      "location_count": 1,
      "location_summary": "Carrollton, Texas",
      "locations": [
        {
          "city": "Carrollton",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05644769"
    },
    {
      "nct_id": "NCT03713268",
      "title": "Intraoperative OCT Guidance of Intraocular Surgery II",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Macular Holes",
        "Epiretinal Membrane",
        "Diabetic Retinopathy",
        "Retinal Detachment",
        "Retinal Disease",
        "Preretinal Fibrosis",
        "Cataract",
        "Ocular Tumor",
        "Strabismus",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Microscope integrated optical coherence tomography",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Weeks and older"
      },
      "enrollment_count": 262,
      "start_date": "2018-09-30",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-26T07:56:34.006Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03713268"
    },
    {
      "nct_id": "NCT04150562",
      "title": "Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clear-Cell Renal Carcinoma"
      ],
      "interventions": [
        {
          "name": "rhIL-15",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-05-26",
      "completion_date": "2021-09-16",
      "has_results": true,
      "last_update_posted_date": "2022-05-17",
      "last_synced_at": "2026-10-26T07:56:34.006Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04150562"
    },
    {
      "nct_id": "NCT03397888",
      "title": "The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Betrixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 32,
      "start_date": "2017-11-16",
      "completion_date": "2018-01-16",
      "has_results": false,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-10-26T07:56:34.006Z",
      "location_count": 1,
      "location_summary": "Hialeah, Florida",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03397888"
    },
    {
      "nct_id": "NCT04234724",
      "title": "Physiological Effects of ANGPTL3 Variants in Humans",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypocholesterolemia"
      ],
      "interventions": [
        {
          "name": "Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2020-12-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-10-26T07:56:34.006Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04234724"
    },
    {
      "nct_id": "NCT06662188",
      "title": "JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SHANK3 Haploinsufficiency",
        "Phelan-McDermid Syndrome"
      ],
      "interventions": [
        {
          "name": "JAG201",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Jaguar Gene Therapy, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "9 Years",
        "sex": "ALL",
        "summary": "2 Years to 9 Years"
      },
      "enrollment_count": 6,
      "start_date": "2024-01-07",
      "completion_date": "2031-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-26T07:56:34.006Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06662188"
    }
  ]
}